Pancreatic Cancer Research

ResearcherOntario Institute for Cancer ResearchActive in the last 2 years

Barbara T. Grünwald

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7541-5206; OpenAlex author ID A5047728701. Sources: OpenAlex.

Their work

Papers
28 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
132
Papers, trials and grants by year

2015: 1 paper · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: 3 papers · 2023: 4 papers · 2024: none · 2025: 5 papers · 2026: 5 papers

Papers 28

  1. Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-026-69013-y↗
  2. Pancreatic cancer. Co-author DOI 10.1038/s41572-026-00699-6↗
  3. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreat… Co-author DOI 10.1200/jco-25-02199↗
  4. Transcriptomic, Genomic, and Clinical Characterization of Morphological Classes in Localized and Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.04.07.717011↗
  5. Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer Co-author DOI 10.64898/2026.10.06.756936↗
  6. Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer. Co-author DOI 10.1038/s41467-024-55330-7↗
  7. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
  8. Transcription factor switching drives subtype-specific pancreatic cancer. Co-author DOI 10.1038/s41588-025-02389-7↗
  9. Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations Co-author DOI 10.1101/2025.08.15.670565↗
  10. The subclonal footprint of pervasive early dissemination in pancreatic cancer Co-author DOI 10.1101/2025.11.27.690823↗
  11. An Engineered Paper-Based 3D Coculture Model of Pancreatic Cancer to Study the Impact of Tissue Architecture and Microenvironmental Gradients on Cell Phenotype. Co-author DOI 10.1002/adhm.202201846↗
  12. Hourglass, a rapid analysis framework for heterogeneous bioimaging data, identifies sex disparity in IL-6/STAT3-associated immune phenotypes in pancreatic canc… Co-author DOI 10.1002/path.6199↗
  13. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02214-0↗
  14. hENT1 as a Predictive Biomarker in PDAC-Response. Co-author DOI 10.1158/1078-0432.ccr-23-0887↗
  15. Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-022-09057-y↗
  16. Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-22-1272↗
  17. Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2022.860767↗
  18. Spatially confined sub-tumor microenvironments in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.09.022↗
  19. TIMP1 expression underlies sex disparity in liver metastasis and survival in pancreatic cancer. Co-author DOI 10.1084/jem.20210911↗
  20. Conformation-Specific Inhibitory Anti-MMP-7 Monoclonal Antibody Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Chemotherapeutic Cell Kill. Co-author DOI 10.3390/cancers13071679↗
  21. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-19-2803↗
  22. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-19-3724↗
  23. Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and… First author DOI 10.1186/s12885-018-4055-9↗
  24. Corrigendum to "Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer" [J. Control. Release 239 (20… Co-author DOI 10.1016/j.jconrel.2017.07.027↗
  25. Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse Model. Co-author DOI 10.1016/j.ajpath.2016.07.025↗
  26. Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2016.08.016↗
  27. Systemic Ablation of MMP-9 Triggers Invasive Growth and Metastasis of Pancreatic Cancer via Deregulation of IL6 Expression in the Bone Marrow. Co-author DOI 10.1158/1541-7786.mcr-16-0180↗
  28. Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2014.10.020↗

Closest collaborators

The 25 strongest of 132 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Grainne Mary O'Kane · 13 shared papers, 2020–2026 · strength 1.83
  2. Steve Gallinger · 13 shared papers, 2020–2026 · strength 1.79
  3. Jennifer Jane Knox · 12 shared papers, 2020–2026 · strength 1.72
  4. Robert C. Grant · 11 shared papers, 2020–2026 · strength 1.65
  5. Faiyaz Notta · 11 shared papers, 2020–2026 · strength 1.58
  6. Rama Khokha · 9 shared papers, 2020–2025 · strength 1.08
  7. Sandra Elisabeth Fischer · 9 shared papers, 2020–2025 · strength 1.05
  8. Jens Thomas Siveke · 5 shared papers, 2016–2026 · strength 0.85
  9. Yifan Wang · 7 shared papers, 2020–2025 · strength 0.83
  10. George Zogopoulos · 7 shared papers, 2020–2025 · strength 0.83
  11. Niklas Krebs · 4 shared papers, 2023–2026 · strength 0.71
  12. Michelle Chan‐Seng‐Yue · 4 shared papers, 2025–2026 · strength 0.70
  13. Kazeera Aliar · 4 shared papers, 2021–2026 · strength 0.63
  14. Erica S. Tsang · 3 shared papers, 2025–2026 · strength 0.54
  15. Achim Krüger · 7 shared papers, 2015–2021 · strength 0.53
  16. Ayelet Borgida · 3 shared papers, 2022–2025 · strength 0.45
  17. Joan Miguel Romero · 4 shared papers, 2020–2025 · strength 0.44
  18. Laura Godfrey · 2 shared papers, 2026 · strength 0.40
  19. Yuanchang Fang · 2 shared papers, 2025–2026 · strength 0.38
  20. Eugenia Flores Figueroa · 2 shared papers, 2025–2026 · strength 0.38
  21. Elisabeth Heßmann · 2 shared papers, 2025–2026 · strength 0.38
  22. Phyllis F. Cheung · 2 shared papers, 2025–2026 · strength 0.37
  23. Sheron Perera · 2 shared papers, 2023–2025 · strength 0.35
  24. Hartland Warren Jackson · 2 shared papers, 2023–2025 · strength 0.34
  25. Spring Holter · 2 shared papers, 2025 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.